Skip to content
Sign in
StableHealthPolicyScienceReported 2026-11-19 01:45

New Treatment Strategy for Down Syndrome Shows Promise in Phase 2 Clinical Trial

A phase 2 clinical trial found that a JAK inhibitor reduced inflammation and improved skin conditions in people with Down syndrome, potentially opening new avenues for brain health and Alzheimer's disease research.

Why it matters. People with Down syndrome may benefit from new treatment options targeting immune dysregulation, which could improve their quality of life and advance research on related conditions.

01

Who and what it touches

Ruxolitinibpart ofbaricitinibpart ofJAK inhibitors

Into JAK inhibitors

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • GGDELT Global Knowledge GraphMedia2026-11-19 01:45
    View source
  • MMedical XpressMedia2026-11-19 05:40
    View source